Retatrutide — Triple Agonist (GLP-1 / GIP / Glucagon)
- HPLC ≥ 98% verified purity
- Lot-specific Certificate of Analysis
- 24-hour nationwide UAE delivery
- Cash on delivery (COD)
- Free shipping over AED 700
- Cold-chain protected shipping
About Retatrutide
Eli Lilly's next-generation triple-receptor agonist — the most studied successor to tirzepatide in clinical research.
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that simultaneously activates three receptors involved in glucose and energy homeostasis: GLP-1, GIP, and glucagon. This triple agonism makes it pharmacologically distinct from the single agonist semaglutide (Ozempic) and dual agonist tirzepatide (Mounjaro / Zepbound).
Originating from Eli Lilly's incretin research programme, Retatrutide has progressed through Phase II clinical trials with body-weight reductions exceeding 24% at 48 weeks — currently the highest reported in any GLP-1-class compound. As a result, it has become one of the most-requested research peptides in metabolic and obesity science.
Research mechanism
Retatrutide's triple agonist activity contributes to its research interest:
- GLP-1 receptor agonism — slows gastric emptying, increases satiety, glucose-dependent insulin release
- GIP receptor agonism — augments insulin response and lipid metabolism (similar to tirzepatide)
- Glucagon receptor agonism — adds an energy-expenditure component absent from single and dual agonists; increases basal metabolic rate
- Documented reductions in hepatic steatosis (fatty liver) in clinical studies
- Documented HbA1c reductions in type 2 diabetes research populations
Retatrutide vs Tirzepatide vs Semaglutide — head-to-head trial data
The three leading incretin research peptides differ in receptor coverage. Phase 2/3 trial numbers below are mean body-weight reduction from baseline at the maximum studied dose.
| Compound (dose) | Receptor Profile | Pivotal Trial | Mean Weight Reduction |
|---|---|---|---|
| Retatrutide 12 mg | GLP-1 + GIP + Glucagon (triple agonist) | Phase 2 (NEJM 2023, 48 weeks) | ≈ 24.2% |
| Tirzepatide 15 mg | GLP-1 + GIP (dual agonist) | SURMOUNT-1 (NEJM 2022, 72 weeks) | ≈ 22.5% |
| Semaglutide 2.4 mg | GLP-1 (mono agonist) | STEP 1 (NEJM 2021, 68 weeks) | ≈ 14.9% |
For a full breakdown of trial data, mechanism, and how the glucagon arm differentiates Retatrutide, read: Retatrutide vs Tirzepatide vs Semaglutide: 2026 Research Comparison
Common companion peptides for Retatrutide research
In our customer protocols, Retatrutide is most often paired with:
Research applications
- Obesity and weight-loss research models
- Type 2 diabetes and glycaemic control studies
- NAFLD / NASH (fatty liver) research
- Metabolic syndrome and cardiometabolic research
- Energy expenditure and thermogenesis studies
- Incretin signalling pathway research
Product specifications
Selected research references
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234-1247.
Frequently asked questions
How is Retatrutide different from Tirzepatide and Semaglutide?
Semaglutide (Ozempic) is a single agonist (GLP-1 only). Tirzepatide (Mounjaro) is a dual agonist (GLP-1 + GIP). Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). The glucagon agonism is the key differentiator, contributing additional energy expenditure absent from earlier-generation compounds.
What's in the 5 mg vs 10 mg vial?
Same peptide, same purity (≥ 99%), different total quantity. The 10 mg flagship vial offers better value per mg for sustained research protocols. Both ship with batch-specific COA.
How do I reconstitute Retatrutide?
For the 10 mg vial, add 3–5 mL bacteriostatic water along the vial wall. Swirl gently — do not vortex. Store reconstituted solution at 2–8°C, protect from light, use within 28 days.
Do you ship Retatrutide across UAE?
Yes — 24h delivery to all 7 emirates. Cold-chain handling for stability. AED 40 delivery, free over AED 700. Cash on delivery.
Order Retatrutide in the UAE today
24-hour delivery to all 7 emirates · Cash on delivery · Free shipping over AED 700
Add to cart WhatsApp inquiry